Novistig (Glycopyrronium Bromide, Neostigmine Methylsulfate)

Glycopyrronium bromide and Neostigmine methylsulfate, the active ingredients in Novistig, are anticholinergic and acetylcholinesterase‑inhibitor agents presented as an intravenous solution for peri‑operative use. They are employed to facilitate reversal of non‑depolarizing neuromuscular blockade and to reduce secretions during anesthesia, allowing safer extubation and recovery.

GNH USA supplies Novistig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and other healthcare facilities worldwide, with consistent quality, regulatory compliance and reliable logistics.

Novistig combines glycopyrronium bromide and neostigmine methylsulfate to act on muscarinic receptors and the neuromuscular junction, respectively, supporting peri‑operative management.

- Reversal of non‑depolarizing neuromuscular blockade: restores muscle strength after surgery. - Control of peri‑operative secretions: reduces salivary and respiratory secretions during anaesthesia. - Management of postoperative residual curarisation: helps eliminate lingering effects of muscle relaxants.

Novistig may be associated with several adverse reactions.

Common Side Effects: - Dry mouth - Facial flushing - Bradycardia - Nausea

Serious or Rare Side Effects: - Bronchospasm - Severe bradyarrhythmia - Anaphylaxis

Use of Novistig requires careful clinical monitoring.

- Cardiac monitoring: observe heart rate and rhythm during administration. - Allergy assessment: discontinue if a hypersensitivity reaction occurs. - Respiratory caution: use carefully in patients with asthma or COPD. - Neuromuscular monitoring: ensure complete reversal before extubation. - Renal impairment: consider dose adjustment in severe renal dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Novistig can interact with other medications; awareness of the interaction level is essential.

Major Interactions (Avoid): - Other anticholinergics: may cause excessive dryness and tachycardia. - Beta‑blockers: can exacerbate bradycardia. - Additional acetylcholinesterase inhibitors: risk of cholinergic excess.

Moderate Interactions (Monitor Closely): - Inhaled anesthetics: may potentiate respiratory effects. - Cardiac glycosides: monitor for arrhythmias. - Diuretics: watch electrolyte balance, especially potassium.